G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
23 Mai 2024 - 11:06PM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology
company, today announced that mature Phase 2 results describing the
positive impact of trilaciclib administered in combination with the
TROP2 antibody-drug conjugate (ADC) sacituzumab govitecan (SG) on
overall survival (OS) and tolerability compared to SG alone based
on historical data from the ASCENT trial will be presented in a
poster session during the upcoming 2024 American Society of
Clinical Oncology (ASCO) Meeting. ASCO will be held May 31 to June
4, 2024, in Chicago, IL. A copy of the poster will be made
available on the G1 Therapeutics website following the presentation
here.
The abstract was made available by ASCO today and includes the
initial Phase 2 trial results originally provided by the Company in
January 2024. The poster that will be presented at ASCO will
describe the mature results of the Phase 2 trial as an update to
the initial results.
Poster Presentation Details: Trilaciclib
Combined with Sacituzumab Govitecan (SG) in Metastatic Triple
Negative Breast Cancer (mTNBC): Updated Phase 2 Safety and Efficacy
Results Seneviratne, L. et al.Poster and abstract number 1091
Poster session: Breast Cancer-MetastaticSunday, June 2, 2024. 9:00
AM-12:00 PM CDT
About G1 TherapeuticsG1 Therapeutics, Inc. is a
commercial-stage oncology biopharmaceutical company whose mission
is to develop and deliver next-generation therapies that improve
the lives of those affected by cancer, including the Company’s
first commercial product, COSELA® (trilaciclib). The Company is
also evaluating therapies in combination with cytotoxic therapies
and/or immunotherapy in areas of high unmet need including
triple-negative breast cancer and extensive stage small cell lung
cancer. G1’s goal is to provide innovative therapeutic advances for
people living with cancer. G1 is based in Research Triangle Park,
N.C. For additional information, please visit
http://www.g1therapeutics.com and follow us on X (formerly known as
Twitter) @G1Therapeutics and LinkedIn.
G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and
the COSELA logo are trademarks of G1 Therapeutics, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
“could”, “believe,” “goal”, “projections,” "estimate," "intend,"
“indicate,” “potential,” “promising,” “opportunity,” “suggest,” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. Forward-looking
statements in this press release include, but are not limited to,
the positive impact of trilaciclib observed in a Phase 2 trial in
combination with sacituzumab govitecan on overall survival and
tolerability compared to SG alone based on historical data from the
ASCENT trial, are based on the company’s expectations and
assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties.
Factors that may cause the company’s actual results to differ from
those expressed or implied in the forward-looking statements in
this press release are discussed in the company’s filings with
the U.S. Securities and Exchange Commission, including the
"Risk Factors" sections contained therein and include, but are not
limited to, the company’s dependence on the commercial success of
COSELA (trilaciclib); the development and commercialization of new
drug products is highly competitive; the company’s ability to
complete clinical trials for, obtain approvals for and
commercialize any of its product candidates; the company’s initial
success in ongoing clinical trials may not be indicative of results
obtained when these trials are completed or in later stage trials;
the inherent uncertainties associated with developing new products
or technologies and operating as a commercial-stage company; and
market conditions. Except as required by law, the company assumes
no obligation to update any forward-looking statements contained
herein to reflect any change in expectations, even as new
information becomes available.
G1 Therapeutics Contacts:
Will RobertsCommunications OfficerVice President, Investor
Relations and Corporate Communications(919) 907-1944
wroberts@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
G1 Therapeutics (NASDAQ:GTHX)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024